Home » Posts tagged with » Merck
Merck acquires Calporta Therapeutics from COI Pharmaceuticals

Merck acquires Calporta Therapeutics from COI Pharmaceuticals

Merck acquisition of Calporta : Merck has acquired Calporta Therapeutics from COI Pharmaceuticals in a deal worth up to $576 million, as per the latest pharma acquisition news. Calporta Therapeutics, which was launched in early 2015, is engaged in the development of selective small-molecule agonists to TRPML1. According to COI Pharmaceuticals, TRPML1 is thought to […]

Chinese biopharma company Akeso raises $150m for antibody drug discovery

Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a Series D funding round. The investment in the clinical stage company was led by Loyal Valley Capital (LVC) and Sino Biopharmaceutical. The co-investors in the Series D round are healthcare […]

Continue reading …
JAVELIN Medley trial : First patient dosed with BAVENCIO, CMP-001 combo

Checkmate Pharmaceuticals announced the dosing of the first patient in a phase 1b/2 study of BAVENCIO (avelumab) in multi-drug combinations with its lead candidate CMP-001 in patients having squamous cell cancer of the head and neck (SCCHN), as part of the JAVELIN Medley trial. CMP‐001 is a C0pG‐A Toll‐like receptor 9 (TLR9) agonist that is […]

Continue reading …
PAOLA 1 trial results : Lynparza, bevacizumab combo achieves PFS goal in phase 3 trial

PAOLA 1 trial results : Lynparza (olaparib), a cancer drug which was jointly developed by AstraZeneca and MSD, in combination with bevacizumab, met the primary endpoint of the phase 3 PAOLA 1 clinical trial in patients with advanced ovarian cancer. The PAOLA 1 primary endpoint is the statistically-significant and clinically-meaningful improvement shown by Lynparza plus […]

Continue reading …
Merck bags Recarbrio FDA approval for urinary tract and intra-abdominal infections

Recarbrio FDA approval : Merck & Co. has secured approval from the US Food and Drug Administration (FDA) for its antibacterial drug product Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of adults having complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Recarbrio is a three-drug combination injection made up of the FDA-approved […]

Continue reading …
Merck to acquire US biopharma company Peloton Therapeutics in $2.2bn deal

Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, according to pharma acquisition news. Based in Texas, Peloton Therapeutics is a clinical-stage company engaged in the development of small molecule therapeutics that target hypoxia-inducible factor-2α (HIF-2α) for the treatment […]

Continue reading …
Pharma giants bag Lynparza EMA approval for metastatic breast cancer

Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency’s (EMA) approval for their poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) to be used for the treatment of a type of advanced breast cancer. The expanded Lynparza EMA approval allows the PARP inhibitor to be used as […]

Continue reading …
Merck to invest €150m to expand Aubonne biotech manufacturing site

Pharma giant Merck revealed its plans to invest €150 million in its Aubonne biotech manufacturing site in Switzerland to expand manufacturing capacity for its biotech medicines. The investment, which will be between 2019 and 2023, will be made on the construction of a new building dedicated to manufacturing the company’s biotech medicines to be supplied […]

Continue reading …
Merck’s EMD Serono to expand biopharma R&D facility with $70m investment

German pharma company Merck will invest $70 million for the expansion of its US and Canada biopharma business EMD Serono’s research and development (R&D) facility in Billerica, Massachusetts. The expansion of the R&D facility through the addition of a new building is expected to enable drug discoveries in the areas of oncology, immuno-oncology and immunology. […]

Continue reading …
Merck bags EU approval for Keytruda chemo combo therapy for NSCLC

Merck has bagged the European Commission approval for the combination of its anti-PD-1 cancer immunotherapy Keytruda (pembrolizumab) with Lilly’s chemotherapy drug pemetrexed (ALIMTA) and platinum chemotherapy for the treatment of a certain form of metastatic nonsquamous non-small cell lung cancer (NSCLC). The latest Keytruda approval is for the use of the cancer combination therapy as […]

Continue reading …
Page 1 of 212